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Abstract
Adeno-associated viruses (AAV) have evolved to exploit the dynamic reorganization of
host cell machinery during co-infection by adenoviruses and other helper viruses. In the
absence of helper viruses, host factors such as the proteasome and DNA damage response
machinery have been shown to effectively inhibit AAV transduction by restricting processes
ranging from nuclear entry to second-strand DNA synthesis. To identify host factors that
might affect other key steps in AAV infection, we screened an siRNA library that revealed
several candidate genes including the PHD finger-like domain protein 5A (PHF5A), a U2
snRNP-associated protein. Disruption of PHF5A expression selectively enhanced trans-
gene expression from AAV by increasing transcript levels and appears to influence a step
after second-strand synthesis in a serotype and cell type-independent manner. Genetic dis-
ruption of U2 snRNP and associated proteins, such as SF3B1 and U2AF1, also increased
expression from AAV vector, suggesting the critical role of U2 snRNP spliceosome complex
in this host-mediated restriction. Notably, adenoviral co-infection and U2 snRNP inhibition
appeared to target a common pathway in increasing expression from AAV vectors. More-
over, pharmacological inhibition of U2 snRNP by meayamycin B, a potent SF3B1 inhibitor,
substantially enhanced AAV vector transduction of clinically relevant cell types. Further
analysis suggested that U2 snRNP proteins suppress AAV vector transgene expression
through direct recognition of intact AAV capsids. In summary, we identify U2 snRNP and
associated splicing factors, which are known to be affected during adenoviral infection, as
novel host restriction factors that effectively limit AAV transgene expression. Concurrently,
we postulate that pharmacological/genetic manipulation of components of the spliceosomal
machinery might enable more effective gene transfer modalities with recombinant AAV
vectors.
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Author Summary
Mammalian cells have developed diverse innate/intrinsic immune strategies to counteract
viral infections. Post-entry infection steps of a single-strand DNA virus, adeno-associated
virus (AAV), are subject to such restrictions. Here, we screened an siRNA library to iden-
tify a novel cellular factor involved in AAV restriction. We found PHF5A, a component of
the U2 snRNP mRNA splicing factor, blocks expression from recombinant AAV vectors.
Disruption of PHF5A expression specifically enhanced AAV vector performance. More-
over, genetic and pharmacological inhibition of other U2 snRNP proteins, but not spliceo-
some proteins involved in other splicing steps, strongly increased transgene expression
from AAV vectors. Further study demonstrated that U2 snRNP proteins recognize incom-
ing AAV capsids to mediate this cellular restriction at the step after second-strand synthe-
sis. In summary, we identify the U2 snRNP spliceosome complex as novel host factors that
effectively restrict recombinant AAV vectors. Considering frequent reorganization of host
splicing machinery in DNA virus infections, it is conceivable that U2 snRNP plays a role
as a broad spectrum antiviral factor and helper viruses have evolved to counteract this
restriction through sequestration of snRNP proteins.
Introduction
Viral pathogens are known to reorganize different components of the host cell machinery dur-
ing the course of infection. For instance, adenoviruses have been shown to induce nuclear reor-
ganization of host splicing factors and mislocalization of the DNA damage response machinery
[1]. Similarly, herpesviruses can induce sequestration of cellular chaperone proteins and the
26S proteasome in nuclear foci to facilitate quality control during replication [2]. Adeno-asso-
ciated viruses (AAV) are helper-dependent parvoviruses that have evolved strategies to repli-
cate efficiently by exploiting host cell co-infection by adenoviruses or herpesviruses [3]. The
infectious pathway of wild type AAV and recombinant AAV vectors consists of multiple stages
starting with cell surface receptor binding, followed by endocytosis, endosomal escape, nuclear
import, second-strand synthesis, and subsequent expression of the vector-encoded transgene
[4,5]. The post-entry steps leading to AAV transduction are particularly subject to restriction
by cell intrinsic factors [6,7,8]. Studies have identified impaired AAV vector transduction due
to inefficient nuclear import [6], uncoating of vector genomes [7], or second-strand synthesis
[8,9]. Treatment with proteasome inhibitors has demonstrated improved transduction by
AAV vectors [10,11], suggesting the involvement of proteasomal degradation pathways in
restricting AAV transduction. Nevertheless, modest increases in accumulation of viral DNA
following proteasomal inhibition cannot solely account for substantial increases in AAV trans-
duction [12], and the underlying mechanism remains elusive. Other host factors such as the
FKBP52 [13], Mre11/Rad50/Nbs1 complex [14,15], APOBEC3A [16] and more recently,
TRIM19/promyelocytic leukemia protein (PML) [17] have been shown to inhibit AAV replica-
tion by blocking second-strand synthesis.
AAV has emerged as a promising vehicle to achieve long-term gene expression with low
toxicity. Recombinant vectors based on naturally occurring AAV serotype capsids and libraries
of engineered capsid mutants have demonstrated unique receptor usages and tissue tropisms,
providing versatility for tissue-targeted gene expression [18,19,20,21,22]. For instance, AAV
vectors with AAV serotype 9 (AAV9) capsid efficiently transduce cardiac tissues, while vectors
with AAV2 capsid show efficient transduction of kidney cells [23,24,25]. Importantly, recent
phase I and phase II clinical trials using AAV vectors have established their safety, in some
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cases, with notable clinical benefits [26,27,28,29,30], opening the door to AAV vector gene
therapies for various human disease conditions. Currently, however, efficient gene transduc-
tion by AAV vectors typically requires high doses of vectors. This presents a major barrier for
the widespread use of AAV vectors in the clinic, due to potential challenges in manufacturing
clinical grade vectors for high dose studies as well as the increased risk of eliciting host immune
responses or inducing insertional mutagenesis at high vector doses [31,32,33]. Improving AAV
vector transduction efficiency would reduce vector doses required for efficient gene delivery,
minimizing the risks associated with high dose AAV vectors. The current report is focused on
the identification of novel host restriction factor(s) that limit expression from AAV vectors as
well as proof-of-principle studies that would enable effective gene therapy with lower vector
doses in clinical trials.
Results
Screening of the siRNA library for proteasomal pathway genes identifies
PHF5A as a factor blocking AAV9 vector transduction
We screened an siRNA library, which covers 600 known and putative human genes in the ubi-
quitin and proteasome pathways, for AAV vector transduction. We identified 12 candidate
genes (Fig 1A). Disruption of those genes in HeLa cells increased luciferase expression by an
AAV9 vector, AAV9 CMV-Luc, over 10-fold (Fig 1A). Further verification with distinct siR-
NAs and lenti-shRNA vectors found disruption of PHF5A, RAB40A and PRICKLE4 reproduc-
ibly increased AAV9 transduction. Treatment of HeLa cells with two PHF5A siRNAs led to
over 80% reduction in PHF5A transcripts (Fig 1B) and increased the transduction by AAV9
vectors up to 12-fold (Fig 1C). In contrast, disruption of PHF5A expression did not strongly
enhance luciferase expression of adenoviral or HIV-based lentiviral vectors (Fig 1D). Similar
results were observed upon disruption of RAB40A and PRICKLE4 (S1 Fig).
To rule out possible off-target effects of siRNA, we generated a lentiviral vector expressing
an siRNA-resistant, HA-tagged PHF5A mutant, PHF5A-HA-Escape (Fig 1E). When endoge-
nous PHF5A expression was disrupted by the PHF5A siRNA, two independent HeLa cell lines
with stable PHF5A-HA-Escape expression (Fig 1E, right panel) did not show enhanced AAV9
vector transduction (Fig 1F). Thus, the increased expression from AAV9 vector by the PHF5A
siRNA is PHF5A-specific, but not due to off-target effects.
PHF5A blocks AAV vector transduction after second-strand synthesis
The AAV CMV-Luc vector construct used in the library screening contained a human beta glo-
bin intron. To rule out the possibility of PHF5A modulating the CMV promoter activity or the
intronic unit, we first replaced the CMV promoter and intron sequence in the AAV vector
genome with an intron-less retroviral SFFV promoter. Disruption of PHF5A increased trans-
duction by multiple AAV serotypes (Fig 2A), indicating that the PHF5A-mediated restriction
was independent from internal promoters or receptors used by AAV vectors. Likewise, knock-
ing down PHF5A was effective at increasing AAV vector transduction in other cell types,
including A375 melanoma cells and primary cardiac fibroblasts (Fig 2B).
Next, we examined the influence of PHF5A ablation on multiple stages of AAV vector
transduction. No notable effects were observed on AAV cellular or nuclear entry (Figs 2C and
S2). Additionally, approximately 30% of total AAV DNA detected was DNase-resistant at 24
hours post infection (p.i.) (Fig 2D), indicating that PHF5A does not affect uncoating process of
AAV vectors. Southern blot analysis demonstrated no notable increase in double-stranded-
monomers in cells pretreated with the PHF5A siRNA (Fig 2E). Upon transduction with a
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GFP-expressing self-complementary AAV (scAAV) vector, which does not rely on second-
strand synthesis for transgene expression, we found significant increases in GFP-expressing
Fig 1. Screening of the siRNA library for proteasomal pathway genes identifies PHF5A as a factor blocking the transduction by AAV9 vector. (A)
Screening of the siRNA library was carried out by reverse transfection of HeLa cells with siRNAs, followed by infection with luciferase-expressing AAV9
vectors (AAV9 CMV-Luc) at a multiplicity of infection (MOI) of 104, and assessment of luciferase expression. Screening of the library identified 12 candidate
genes that increased transduction by AAV9 vectors over 10-fold. Further studies were carried out in HeLa cells transfected/transduced with specific siRNAs
or shRNA lentivectors for each of the 12 genes to verify the screening candidates. (B)Quantitative real-time RT-PCR was performed to determine the levels
of PHF5A transcripts in cells treated with control or PHF5A siRNAs at 48 hours. (C) HeLa cells were transfected with control or PHF5A siRNAs for 24 hours,
followed by infection with AAV9 CMV-Luc vectors (MOI 104) for an additional 48 hours. The luciferase assay was performed in order to determine relative
luciferase activities in treated cells. (D) Same as C, except that a luciferase-expressing adenoviral vector at an MOI of 3 x 102 or an HIV-1-based lentiviral
vector (MOI 0.3) were used to infect siRNA-treated HeLa cells. (E) Lentiviral vector pSIN-PHF5A-Escape with the PHF5A-HA Escape transgene was
generated through introduction of three silent mutations in the PHF5A siRNA#1-targeted sequence. Western blotting was performed to verify the expression
of the PHF5A-HA-Escape and its resistance to the PHF5A siRNA#1 treatment. Anti-PHF5A antibody was used to detect endogenous and over-expressed
PHF5A-HA, while anti-HA antibody detected the HA-tagged PHF5A. (F) HeLa cell lines stably expressing the PHF5A-HA-Escape mutant were generated
through lentiviral transduction of the escape mutant, followed by puromycin selection. Upon treatment with the PHF5A siRNA and AAV9 CMV-Luc vector
(MOI 104), luciferase expression was determined in control HeLa and PHF5A-HA-Escape-expressing HeLa cells. (B-D, F) Data are shown as averages of
three independent experiments with error bars representing standard error of the mean. *p<0.05.
doi:10.1371/journal.ppat.1005082.g001
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Fig 2. PHF5A blocks AAV vector transduction after second strand synthesis. (A) HeLa cells pre-treated with control or PHF5A siRNAs for 24hr were
transduced with AAV9, 2, 6 or 8 vectors (MOI 104) expressing luciferase under the control of the SFFV retroviral promoter with no splicing unit. Relative
increase in luciferase expression was determined 48 hours p.i. Averages of three independent experiments were shown. Error bars represent standard error
of the mean. (B)Melanoma A375 cells and primary human fibroblasts were pre-treated with siRNAs for 24 hours, followed by transduction with the AAV2
CMV-Luc vector (MOI 104) for 48 hours. (C) HeLa cells were pre-treated with siRNAs for 24 hours and infected by the AAV9 CMV-Luc vector (MOI 8 x 104).
Total cytoplasmic and nuclear DNA were isolated and AAV luciferase vector genome copies were determined by quantitative real-time PCR at 2, 6 and 24
hours p.i. All samples were prepared in duplicate, and results represent the average of three separate experiments. (D) Same as C, but total DNA at 6 hours
p.i. was used to determine total and DNase-resistant AAV genome copies and assess the percent DNase-resistant AAV genomes. Samples were in
duplicate and results show the average of two independent experiments. (E) siRNA-treated HeLa cells were infected with AAV9 CMV-Luc vector (MOI 8 x
104) for 1, 3 or 6 hours. Total nuclear DNA samples were used to detect the vector-derived single-stranded and double stranded monomers by Southern
blotting. (F)HeLa cells were transfected with siRNAs for 24 hours, followed by infection with a GFP-expressing self-complementary (sc) AAV9 vector (MOI 2
x 104) for 48 hours. Flow cytometry analysis was performed to quantify GFP-positive cell populations. The graph represents percentage of GFP-positive cells
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cell populations in HeLa cells treated with the PHF5A siRNA (Fig 2F). These results indicate
that PHF5A blocks the process of AAV vector transduction after second-strand synthesis. We
then explored the effects of PHF5A disruption on the transcription of AAV9 CMV-Luc vector.
Northern blot analysis showed that pretreatment with the PHF5A siRNA increased the levels
of luciferase-specific transcripts (Fig 2G and 2H), suggesting that PHF5A affects the step before
translation. When HeLa cells were transfected with the AAV vector genome plasmid, pAAV
CMV-Luc, or single-stranded AAV vector genomic DNA from purified AAV vector particles,
PHF5A ablation caused no increase in luciferase expression of transfected viral genome (Fig
2I). Together, this suggests that PHF5A acts to restrict AAV vector transduction somewhere
between AAV second-strand synthesis and the transcription of the AAV vector transgene. It
also appears that PHF5A does not directly target AAV vector genome. Additionally, introduc-
tion of disruptive mutations in any of the three GATA-type zinc finger motifs in PHF5A led to
the loss of anti-AAV activity (S3 Fig).
The U2snRNP complex plays a key role in restricting AAV vector
transduction
PHF5A has been reported to interact with various proteins, including the U2 snRNP proteins,
SF3B1, SF3B2, SF3B3 [34,35,36], U2AF1, ATP-dependent helicases EP400 and DDX1, and
arginine-serine-rich domains of splicing factor SFRS5 [36]. Additionally, through co-immuno-
precipitation of HA-tagged PHF5A, we identified potential PHF5A-interacting proteins,
including FUS, EEF1, EEF2 and HIST1H4B. To further understand the underlying mechanism,
we assessed the effects of disrupting those proteins on expression from AAV vectors. After ver-
ification of reduction in corresponding transcripts upon transfection of specific siRNAs (S4A
Fig), siRNA-treated cells were infected with AAV9 CMV-Luc vectors at 24 hours post transfec-
tion, with luciferase activity assayed 48 hours p.i. Ablation of U2 snRNP components and
U2 snRNP-associated factor (U2AF1) resulted in a substantial increase in luciferase activity
relative to HeLa cells pre-treated with a control siRNA (Figs 3A and S4B). Disruption of
HIST1H4B, one of histone H4 genes, also showed a modest increase, while ablation of other
factors showed no notable effect. Of note, disruption of spliceosome proteins involved in other
splicing steps, including SNRNP200 and PRPF31, essential factors for U4/U6-U5 formation
and function, did not increase the AAV vector transduction (S4A and S4B Fig). These results
suggest that PHF5A blocks AAV vector transduction through an interaction with U2 snRNP
proteins and associated U2AF1, independently of cellular RNA spliceosome function. Similar
to the effects of PHF5A knockdown, disruption of U2 snRNP components or U2AF1 did not
enhance the luciferase expression from an adenoviral vector or a transfected AAV vector plas-
mid, pAAV CMV-Luc (Fig 3B and 3C). Taken together, we conclude that infectious AAV
particles and all steps in intracellular trafficking pathway are essential for the restriction of
transduction by U2 snRNP and associated proteins.
To further confirm the role of U2 snRNP proteins in the restriction of AAV vectors, we
assessed the influence of pharmacological inhibition of U2 snRNP on expression from AAV
vectors. One drug we employed was meayamycin B, a potent SF3B1 inhibitor, synthesized
according to the literature [37]. When HeLa cells were pre-treated with this drug at an
from the R2-gated population. (G) HeLa cells were pre-treated or untreated with siRNAs for 24 hours, followed by transduction with the AAV9 CMV-Luc
vector (MOI 4 x 105) for 36 hours. Nuclear and cytoplasmic RNA samples were subject to the Northern blotting analysis for detection of the luciferase
transcripts. (H) HeLa cells were treated with no siRNA, control or PHF5A siRNAs for 24 hours and then transduced by AAV9 CMV-Luc (MOI 2 x 105). Thirty-
six hours p.i., cells were harvested and levels of luciferase transcripts were determined by RT-qPCR. (I) HeLa cells were pre-treated with control or PHF5A
siRNAs for 24 hours, followed by transfection with purified AAV CMV-Luc genomic DNA (0.1 μg/well). Luciferase activities were determined at 48 hours p.i.
*p<0.05.
doi:10.1371/journal.ppat.1005082.g002
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increasing dose 3 hours before AAV9 vector infection, dose-dependent increases (up to
49-fold) in relative luciferase activity were seen (Fig 3D). As we reported previously, treatment
of HeLa cells with over 20 nM of meayamycin B for two days showed cytostatic effects [37]. A
related SF3B1 inhibitor, meayamycin, also demonstrated a substantial increase in AAV trans-
duction (S4C Fig). In contrast, other drugs reported to block other splicing steps, including iso-
ginkgetin at the prespliceosome/A complex stage [38] and 3-Aminophenylboronic acid (ABA)
at the second stage (excision of the lariat intron), did not show notable increases in AAV vector
transduction (Figs 3E and S4D) although isoginkgetin blocked cellular mRNA processing (Fig
3F). Of note, a low dose (5 nM) meayamycin B treatment substantially enhanced AAV vector
transduction without strongly affecting mRNA splicing (Fig 3D and 3F), indicating that inhibi-
tion of the general splicing process is not necessary to enhance AAV vector transduction. Addi-
tionally, we found that pretreatment with the drug is not needed in order for it to enhance
AAV vector infection (Fig 3G). The largest increase in luciferase activity (464-fold) was
observed when cells were treated by meayamycin B 9 hours p.i. In contrast, treatment at 33
hours post p.i. showed relatively weak effects. To further map the optimal timing of U2 snRNP
inhibition for AAV vector transduction, we treated AAV2 and AAV9 vector-infected HeLa
cells with 5 nMmeayamycin B at various time points and duration, and assessed luciferase
activity at 3 days p.i. Treating with meayamycin B 3 hours p.i. and washing cells 1, 2 or 3 days
after receiving the drug resulted in similarly high levels of enhanced luciferase expression (S4E
Fig). Washout of meayamycin B for 48 hours after 3–24 hours of treatment did not strongly
compromise its effects on AAV vector transduction. In contrast, the effects of meayamycin B
on AAV vector transduction were impaired when drug was added either 24 or 48 hours p.i.
(S4E Fig). Thus, optimal enhancement of AAV vector transduction requires initiation of U2
snRNP inhibition prior to 24 hours post AAV vector infection. This indicates that U2 snRNP
blocks AAV vectors at a particular post-entry step of viral infection, likely occurring before 24
hours p.i. Similar to PHF5A disruption, meayamycin B also enhanced the transduction by both
single-stranded AAV and scAAV vectors through increasing the number as well as the fluores-
cent intensity of GFP-positive cells (Fig 3H). In addition, dual treatments with meayamycin B
and PHF5A or SF3B1 siRNAs showed no additional impact on the AAV vector transduction
(Figs 3I and S4F), verifying that meayamycin B and PHF5A/SF3B1 target a common pathway.
On the other hand, dual treatment with a proteasomal inhibitor MG132 and meayamycin B
showed a synergistic effect (Fig 3J), indicating that the U2 snRNP proteins block AAV
Fig 3. The U2snRNP complex plays the key role in restricting AAV vector transduction. (A)HeLa cells were transfected with control siRNA, or siRNAs
targeting PHF5A, histone 4, U2AF1, SF3B1, SF3B2 and SF3B3 for 24 hours, followed by the AAV9 CMV-Luc vector transduction (MOI 104). Relative luciferase
expression was determined 48 hours p.i. (B) Same as A, but luciferase-expressing adenoviral vector was used to transduce siRNA-treated cells (MOI of 3 x
102). (C) Same as A, except that the siRNA-treated cells were transfected with the vector genome plasmid, pAAV CMV-Luc (0.2 μg/well)for 48 hours. Note that
this plasmid was used to generate the infectious AAV9 CMV-Luc vector used in (A). (D)HeLa cells were treated with increasing concentrations of U2 snRNP
inhibitor, meayamycin B, followed by transduction with the AAV9 CMV-Luc vector (MOI 104). Relative luciferase expression was determined 48 hours p.i. (E)
Same as D, except that a prespliceosome/A complex inhibitor, Isoginkgetin, was used. (F)HeLa cells were treated with indicated spliceosome inhibitors for 8
and 24 hours and levels of unspliced and spliced cellular MAPT (microtubule associated protein tau) transcripts were determined by RT-PCR. (G)HeLa cells
were treated with 20 nMmeayamycin B at various time points before or after AAV9 CMV-Luc vector infection (MOI 104). Relative luciferase expression was
determined 48 hours p.i. (H)HeLa cells were infected by AAV9 CMV-GFP (MOI 103) or scAAV9 CMV-GFP vectors (MOI 6 x 103), followed by treatment with 20
nMmeayamycin B at 8 hours p.i. Flow cytometry analysis was performed to see GFP-positive cell populations at 48 hours p.i. (I)Co-treatment of HeLa cells with
SF3B1 siRNA and Meayamycin B. HeLa cells were treated with the siRNAs for 48 hr, followed by infection with AAV9 CMV-Luc (MOI 104). At 9 hours p.i.
Meayamycin B (5nM) was added, and cells were harvested for the luciferase assay 48 hours p.i. (J)Co-treatment of HeLa cells with MG-132 and Meayamycin
B. 30min prior to AAV infection cells were treated with MG-132. 9 hours after infection with AAV9 CMV-Luc (MOI 104), cells were treated with meayamycin B,
and harvested for luciferase assay 20 hours later. Due to notable toxicity of MG-132, we needed to harvest cells at this early time point. (K) Influence of dual
treatment with human adenovirus 5 infection and SF3B1 disruption on AAV vector infection. HeLa cells were treated with control or SF3B1 siRNAs for 24 hours,
followed by infection with AAV2 CMV-Luc (MOI 104) or co-infection with AAV2 CMV-Luc and human adenovirus 5 (MOI 3 x 104) for 48 hours. (L) Influence of
adenovirus 5 infection on subcellular localization of SF3B1 in HeLa cells. HeLa cells were infected with human adenovirus 5 (MOI 104) for 24 hours, and SF3B1
in control and infected HeLa cells was visualized by anti-SF3B1 antibody (red). Nuclei were counter-stained by DAPI (blue). (A-E, G, I, J and K) Samples were
run in triplicate and results are the average of two independent experiments. *p<0.05.
doi:10.1371/journal.ppat.1005082.g003
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restriction independently from the proteasomal pathway. We also tested the influence of ade-
novirus co-infection on the U2 snRNP-mediated restriction of AAV vectors. Although human
adenovirus 5 (Ad5) co-infection alone enhanced AAV2 transduction 30-fold (Fig 3J), dual
treatments of Ad5 co-infection and SF3B1 knockdown showed minimal additive effects on
AAV transduction (Fig 3K). Similar results were observed with meayamycin and Ad5 dual
treatments (S4G Fig). These results strongly suggest that Ad5-mediated activation of AAV vec-
tor transduction is through U2 snRNP inhibition. Indeed, when the influence of Ad5 infection
on subcellular localization of U2 snRNP was determined, Ad5 infection showed notable
PHF5A and SF3B1 displacement in HeLa cells (Figs 3L and S4H). On the other hand, meaya-
mycin B treatment failed to increase AAV vector production, or rescue AAV vector production
in the absence of the adenovirus helper plasmid (S4I Fig), suggesting that U2 snRNP inhibition
is not sufficient to provide adenoviral helper function during AAV production.
PHF5A and U2 snRNP component SF3B1 interact with AAV capsid
Next, we assessed the interaction between PHF5A and AAV vector components. Upon pull-
down of HA-tagged PHF5A from AAV vector-infected cells (Figs 4A and S5), total DNA in
the pellets was assessed for AAV vector genomes. Quantitative real-time PCR detected signifi-
cantly more AAV vector genome DNA in the HA pulldown from PHF5A-HA-over-expressing
cells as opposed to control cells (Fig 4B). We also tested the influence of heat-mediated confor-
mational changes of viral capsids, which lead to the exposure of the hidden VP1 N-terminal
and viral genomic DNA [39,40], on the interaction with PHF5A. A three-fold increase in AAV
genome copies was detected in the HeLa-PHF5A-HA pulldown when the cell lysates were
incubated with pre-heated AAV2 CMV-Luc vector than non-heated vector (Fig 4C). Those
data indicate interaction of PHF5A with AAV vector genome, directly or indirectly.
Next, immunohistochemistry was performed in order to identify the subcellular localization
of PHF5A and AAV capsid. The A20 anti-AAV2 capsid antibody was used to detect AAV cap-
sids (Fig 4D). The majority of AAV capsid signals were found in the cytoplasm at 4 and 12
hours p.i. (Fig 4D). Although endogenous PHF5A was predominantly found in the nucleus,
especially in the nucleoli, of uninfected cells (Fig 4D), a notable increase in cytoplasmic PHF5A
signals was found in AAV2 vector-infected cells at 1 and 4 hours p.i. (S6A Fig). Of note, AAV2
capsid signals frequently co-localized with the cytoplasmic PHF5A body signals (Fig 4E).
When HeLa cells were exposed to an empty AAV2 vector, similar cytoplasmic recruitment of
PHF5A to AAV2 capsids was also evident (Fig 4E, lower panels), suggesting that the PHF5A
translocation (or de novo recruitment in the endosome) to AAV2 capsids is independent of
AAV vector genome. Analysis of Z-stack images of AAV-infected cells at 4 hours p.i. showed
comparable perinuclear and nuclear accumulation of AAV capsids between control and the
PHF5A-siRNA treatment, further supporting that PHF5A does not affect AAV vector traffick-
ing and nuclear import (Figs 4F and S7).
When the subcellular localization of the major U2 snRNP component, SF3B1, was assessed,
nuclear speckles in the nucleoli and a diffuse cytoplasmic signal were observed (S8A Fig).
Although the widespread SF3B1 signals often overlapped with the AAV2 capsid signals, the
diffuse cytoplasmic signal made it difficult to verify co-localization with AAV2 vector particles
(S8B Fig). To validate the AAV2 capsid and SF3B1 interaction, we employed the gradient tech-
nique to separate free-SF3B1 forms from particulated AAV capsid-associated SF3B1 (Fig 4G),
which was used to determine the interaction between retroviral capsids and a cytoplasmic ret-
roviral restriction factor TRIM5alpha [41]. Upon ultracentrifugation through the 25% iodixa-
nol layer, AAV2 capsid proteins VP1, VP2 and VP3 (87, 72, 62 kDa) were detected in the
pellets (Fig 4H). When the same samples were probed for SF3B1 (175 kDa), endogenous
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SF3B1 was seen in the input and upper layer samples of untreated HeLa cells (Fig 4H). In
AAV2-treated lysates, additional SF3B1 bands were seen in the pellet (Fig 4H, S8C and S8D
Fig). When the co-precipitation of PHF5A with AAV2 capsid was assessed, no intact PHF5A
protein bands (15 kDa) were detected after incubation at 4°C for 1 hour, likely due to its insta-
bility (Fig 4H). Instead, multiple high molecular weight signals were detected in the input and
top layer samples by anti-PHF5A and anti-HA antibodies (Figs 4H and S8D). Notably, high
molecular weight PHF5A signals were detected in the pellet of AAV2-treated samples but not
in the pellet of untreated samples. It is possible that PHF5A is modified (or modifies other pro-
teins) upon interaction with AAV components. To further map the responsible region for the
interaction between SF3B1 and AAV2 capsid, we performed the same experiments using
empty AAV capsid, made with the VP3 protein alone. The VP3-only capsid was able to enrich
SF3B1 in the pellets (Fig 4I). In contrast, multiple attempts to enrich SF3B1 or PHF5A through
pulling down non-assembled VP1 proteins were unsuccessful (Fig 4J). These results suggest
that U2 snRNP proteins interact with the AAV2 capsid structure within the VP3 region, but
not AAV2 vector genomic DNA or non-assembled AAV2 VP1 protein.
Meayamycin B increases AAV vector transduction of clinically relevant
cell types
Finally, we tested the ability of meayamycin B to boost AAV transduction in various cell types,
relevant to gene therapy applications. When primary pancreatic islets were transduced with
AAV8 CMV-GFP and treated with 2 nMmeayamycin B 3 hours p.i., there were increased
numbers of GFP expressing cells in drug treated mouse islets (Fig 5A). When primary human
pancreatic islets were infected with AAV2 or AAV9 CMV-Luc vectors and treated with 0, 2, 5,
or 20 nMmeayamycin B at 7 hours p.i., we found dose-dependent increases in luciferase
expression in AAV2 and AAV9 infected cells (Fig 5B). Likewise, meayamycin B treatment
increased AAV2 and AAV9 transduction of primary neonatal rat cardiomyocytes as well as
porcine hepatocytes (Fig 5C and 5D). These results demonstrate that meayamycin B enhances
AAV vector transduction of a variety of cell types from different host species. Although we typ-
ically observed no notable toxicity in primary cells treated with 5 nMmeayamycin B, pro-
longed treatment with over 10 nMmeayamycin B showed anti-proliferative effects as we
reported previously [42]. Since meayamycin B is rapidly cleared from circulation by unknown
mechanism(s) [42], we were unable to evaluate drug doses high enough to test the impact on
AAV vector transduction in vivo.
Fig 4. PHF5A and U2 snRNP component SF3B1 interact with AAV capsid. (A) HeLa or PHF5A-HA-expressing cell lysates were used to pull-down the
HA-tagged PHF5A by anti-HA agarose beads. After 15 washes, the HA-tagged PHF5A was detected by anti-HA antibody. (B) Control or PHF5A-HA-
expressing HeLa cells were transduced by AAV2 and AAV9 CMV-Luc vectors (MOI 4 x 105) and total AAV genome copies in the HA pulldown were
determined by quantitative real-time PCR. (C) AAV2 CMV-Luc vector (3 x 1010 genome copies) was unheated or preheated for 30 min at 65°C. PHF5A-HA-
over-expressing HeLa cell lysates were then incubated with vectors for 1 hour at 4°C, followed by pulldown of PHF5A-HA. AAV vector genome copies in the
precipitates were determined by quantitative real-time PCR. (D) HeLa cells were infected with the AAV2 CMV-Luc vector (4 x 1010 genome copies/well) for 5
min, 4 or 12 hours. Confocal microscopy analysis was performed to detect the subcellular localizations of AAV vector particles (green) and PHF5A (red).
Nuclei were counterstained by DAPI (blue). (E) HeLa cells were infected with AAV2 CMV-Luc vectors (4 x 1010 genome copies/well) or equivalent amounts of
empty AAV2 vectors for 4 hours, and cells were analyzed for co-localization of AAV2 capsid and endogenous PHF5A signals. Prominent co-localized signals
were indicated by white arrows. (F) HeLa cells were treated with the PHF5A siRNA for 24 hours, followed by transduction with the AAV2 vector as in E for 4
hours. AAV2 vector particles were detected by anti-AAV2 capsid A20 antibody, and the patterns of cytoplasmic and nuclear accumulations of AAV2 vector
particles were compared between control and PHF5A-ablated cells. Representative Z-stack images of the middle sections (slices 3 and 4) from control and
PHF5A knockdown cells are shown. (G) Schematic representation for the iodixanol cushion method to enrich cellular factors interacting with particulated
AAV capsids. (H) HeLa cell lysates were incubated with AAV2 CMV-Luc vectors (5 x 1010 genome copies) for 1 hour at 4°C. After centrifugation over 25%
iodixanol, three layers (the upper phase, lower phase, and pellet) were separately harvested for Western blotting. AAV capsid proteins VP1, 2 and 3,
phospho-SF3B1, and endogenous PHF5A were detected by A20, anti-SF3B1, and anti-PHF5A antibodies, respectively. (I) Same as H for AAV capsid
proteins, except that empty AAV2 VP3 only capsids were used for SF3B1 co-precipitation. (J) Control or AAV VP1-over-expressing 293T cell lysates were
used to pull-down the AAV VP1 protein by A20 antibody. After 15 washes, the pellets were probed for SF3B1 enrichment by anti-SF3B1 antibody.
doi:10.1371/journal.ppat.1005082.g004
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Fig 5. Meayamycin B increases AAV vector transduction of clinically relevant cell types. (A) Primary
mouse islets were infected with AAV8 CMV-GFP in the presence or absence of 2 nMmeayamycin B, and
GFP expression was monitored for three days. (B) Primary human islets were treated with AAV2 or AAV9
CMV-Luc vectors for 7 hours and then treated with 0, 2, 5 or 10 nMmeayamycin B. Luciferase expression
was analyzed 48 hours p.i. (C)Neonatal rat cardiomyocytes were infected with AAV2 CMV-Luc or scAAV9
CMV-GFP vectors and treated with meayamycin B, 3 hours p.i. Luciferase activity was measured 3 days p.i.,
while GFP expression was monitored at 5 days p.i. (D) Porcine hepatocytes were infected with AAV2 or
AAV9 CMV-Luc vectors for 8 hours, virus was then removed and cells were treated with 0, 2, or 20 nM
meayamycin B. Cells were harvested 48 hours p.i. for the luciferase assay. In A-D, an MOI of 104 was used.
doi:10.1371/journal.ppat.1005082.g005
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Discussion
Here, we have demonstrated that PHF5A and U2 snRNP proteins, such as SF3B1, restrict AAV
vector transduction through recognition of incoming AAV capsids. Of particular relevance to
gene therapy applications, genetic and pharmacological inhibition of PHF5A or U2 snRNP-
associated proteins strongly increased the transduction efficiency of AAV vectors. Thus, tran-
sient suppression of U2 snRNP or designing AAV vectors to avoid this restriction can provide
a novel strategy to achieve efficient AAV vector transduction with reduced vector doses, which
in turn could lead to improved safety profiles for AAV-mediated gene therapy applications.
Several strategies have demonstrated the potential to enhance AAV vector transduction
efficiency, including treatments with genotoxic agents [43,44,45], adenoviral E1b55k/E4orf6
proteins [14], a specific EGFR protein tyrosine kinase inhibitor (Tyrphostin-23) [46], and pro-
teasome inhibitors [10,11]. A major effect of the genotoxic treatments, such as hydroxyurea
and topoisomerase inhibitors, is improved double-strand synthesis of the input vector genome
[8,9,47]. In contrast, the adenoviral proteins degrade the cellular Mre11 repair complex (MRN)
to promote AAV vector transduction as well as provide crucial helper functions for wild-type
AAV replication [14], although a recent study suggests a role for MRN in gene expression [15].
Tryphostin-23 dephosphorylates FKBP52, a protein binding to the viral single-strand DNA,
and improves viral second-strand DNA synthesis [46] and intracellular trafficking of AAV vec-
tors [48]. Importantly, Tryphostin-23 does not show a synergistic effect with the proteasome
inhibitor MG132, suggesting that both drugs target a common step of AAV vector transduc-
tion [12,48]. We found U2 snRNP inhibition had no notable effect on AAV vector second
strand synthesis. Although we initiated the screening of the study using a commercially avail-
able siRNA library targeting known and putative proteasomal pathway proteins, MG132 treat-
ment showed an additive effect with SF3B1 inhibition, suggesting U2 snRNP inhibition and
MG132 work on distinct pathways. In contrast, dual treatments with Ad5 co-infection and
SF3B1 inhibition showed no additive effect, suggesting a common target shared by Ad5 and
SF3B1 inhibition. Since Ad5 infection induced PHF5A and SF3B1 displacement, it is plausible
that Ad5 co-infection increases expression from AAV vectors, at least in part, through U2
snRNP inhibition.
Dissection of the mechanism by which PHF5A and U2 snRNP components block AAV vec-
tor transduction might allow rational design of next generation AAV vectors that can poten-
tially circumvent this host restriction machinery. Based on the following observations, we
conclude that U2 snRNP restricts AAVs at an early stage of infection. First, optimal enhance-
ment of AAV vector transduction required U2 snRNP inhibition at an early time point post
AAV vector infection (3–24 hours p.i.), while washout of a U2 snRNP inhibitor for the follow-
ing 2 days did not impair the effects. Thus, short-term U2 snRNP suppression appears to
change the fate of AAV vectors up to 2 days post-incubation. Secondly, U2 snRNP inhibition
showed no enhancing effect when purified AAV vector genomic DNA or AAV vector genome
plasmids were introduced by transfection. Third, although PHF5A was predominantly found
in the nuclei in uninfected HeLa cells, we found frequent co-localization of AAV vector parti-
cles and PHF5A signals, both in the nucleus and the cytoplasm of cells exposed to AAV vectors.
We speculate that newly synthesized PHF5A likely interacts with incoming AAV capsids in the
cytoplasm. Finally, pull-down and capsid co-precipitation assays using AAV vectors and
empty AAV particles indicate that PHF5A and SF3B1 interact with the capsid, likely mediated
by domains within the VP3 region. Of note, the use of heated AAV particles, which leads to
exposure of the hidden VP1 N-terminal and viral genome release [39,40,49], increased co-pre-
cipitation of capsid-associated AAV genome by PHF5A pull-down, or SF3B1 co-precipitation
by the capsid. Consistent with these observations, previous studies have demonstrated the
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majority of viral DNA can remain associated with the capsid upon thermally induced DNA
release [40]. A recent study has also implicated AAV capsid proteins in playing a role in second
strand synthesis as well as the transcription of vector genomes [50], supporting prolonged asso-
ciation of AAV capsid proteins with vector genomes at the time of transcription in the nucleus.
Taken together, our results strongly support the notion that direct interaction of PHF5A and
U2 snRNP components in a cooperative fashion with conformationally altered AAV capsids
and the exposed vector genome blocks subsequent transcription.
Although the exact mechanism is currently under investigation, one potential path being
explored hinges on the involvement of U2 snRNP proteins in chromatin regulation. For
instance, Isono et al. [51] have reported the essential role of SF3B1 (and likely other U2 snRNP
proteins) in mammalian polycomb-mediated epigenetic silencing of homeotic genes. Sudemy-
cin E, a U2 snRNP inhibitor, has also been shown to cause changes in histone modifications
[52]. SF3B1 and SF3B2 are also found to associate with the histone H3 tails [53]. The ability of
PHF5A and SF3B proteins to recruit additional factors to the AAV capsid and its associated
vector genome is currently unknown, but if true these findings would provide further insight
into the mechanism of host restriction. Further insight into the latter mechanism can poten-
tially be derived from earlier reports that suggest that the splicing machinery is significantly
remodeled during host cell infection by helper viruses such as adenoviruses [54]. As outlined
earlier, the spatial organization of host splicing factors into distinct clusters within the nucleus
appears to be regulated during adenoviral infection [1,55]. Similarly, herpes simplex virus
infection induces snRNP-containing bodies [56] through interaction between IE63 protein
(ICP27) with SF3B2 (SAP145) [57]. Thus, it is tempting to speculate that wild type AAVmight
have evolved to exploit the mislocalization/sequestration of splicing factors during helper virus
co-infection, while recombinant AAV are unable to evade such host restriction factors in the
absence of helper viruses. It is also possible that U2 snRNP plays a role as a broad spectrum
antiviral factor, while helper viruses have evolved to counteract this restriction through seques-
tration of snRNP proteins.
Based on the aforementioned reasons, our current working model is the U2 snRNP recogni-
tion of incoming AAV capsid, leading to subsequent block of AAV transcription. However,
some observations suggest potential U2 snRNP-mediated AAV restriction at a late stage of
transduction. For instance, at very late time points in infection in cell cultures, there was still a
substantial enhancement in AAV vector (100-fold at 24 hr and 20-fold at 33 hr p.i.). At this
late time point, most of the genomes are considered to be in the nucleus, and it is less likely
that U2 snRNP can target incoming AAV capsid. One plausible explanation is that U2
snRNP can also target AAV genome-associated capsid in the nucleus for blocking AAV vector
expression. Another point is on our Northern blot analysis of vector transcripts upon PHF5A
knockdown. We found a notable increase in cytoplasmic AAV transcripts, but lesser degree in
nuclear transcripts. Thus it remains possible that U2 snRNP can also target the nuclear export/
cytoplasmic accumulation of AAV transcripts. Another caveat of our experimental system was
the use of rapidly dividing cells, where some, or even the majority, of vector genomes can be
lost at later time points.
In addition to mechanistic analysis, we have compared FR901464 analogs and herboxidiene,
and have identified that meayamycin B is the most potent SF3B1 inhibitor [58]. Importantly,
treatment with meayamycin B substantially enhanced AAV vector transduction in various clin-
ically relevant cell types, including primary cardiomyocytes, pancreatic islets and hepatocytes.
Thus, pharmacological inhibition of U2 snRNP components may provide a novel strategy to
improve AAV vector transduction. Unfortunately, however, intravenous administration of
meayamycin B leads to rapid clearance, likely due to absorption, distribution, metabolism and/
or excretion [42]. Additionally Meayamycin B also has a potent anti-proliferative effect at
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higher doses [37,58]. These features present a barrier to immediate in vivo applications of
meayamycin B for improved AAV gene delivery. Nevertheless, since a low dose meayamycin B
substantially increased AAV vector transduction without strongly affecting host RNA splicing
in vitro, designing a novel U2 snRNP inhibitor with reduced cytostatic effects and in vivo sta-
bility may allow co-administration of the inhibitor with AAV vectors for improved AAV gene
therapy with reduced vector doses.
In conclusion, we demonstrate that the U2 snRNP spliceosome inhibits AAV vector trans-
duction and genetic/chemical modulation of this machinery improves transduction efficiency.
This finding may lead to approaches that might help reduce AAV vector doses in clinical appli-
cations. Further understanding the underlying mechanism would provide novel insights into
host-virus interactions and could inform the rational or combinatorial design of next genera-
tion AAV vectors with improved transduction efficiency and safety profile.
Materials and Methods
Ethics statement
Primary human islets were obtained through the Integrated Islet Distribution Program (IIDP)
and the use of the cells was approved by the Mayo Institutional Review Board (IRB10429). All
animal experiments were conducted according to the National Institute of Health guidelines
and approved by the Institutional Animal Care and Use Committee (IACUC A33214 and
IACUC A9014).
Plasmids
pAAV-CMV-Luc vector genome construct, which drives firefly luciferase expression by a CMV
internal promoter followed by the human beta globin intron, was described previously [24].
pAAV-SFFV-Luc was generated by replacing the CMV promoter and the beta globin intron
region by Mlu1-BamHI with the intron-less SFFV retroviral promoter from a lentiviral vector
plasmid, pSIN-Luc. The HA-tagged wildtype PHF5A-expressing lentiviral vector, pSIN-PH-
F5A-HA, was constructed by amplifying the human PHF5AORF (GenBank accession number
BC075808) in pCMV-SPORT6 (OpenBiosystems, MHS1010-97228317) by primers with a 3’
hemagglutinin (HA) tag, followed by cloning into the BamHI and NotI sites of a pHR-SIN
CSGWPGK Puro (gift from Prof. Paul J. Lehner). Site-directed mutagenesis was performed to
generate pSIN-PHF5A-Escape, with three point mutations in the PHF5A siRNA #1 targeting
site. Further site-directed mutagenesis was performed to generate zinc finger mutant vectors,
pSIN-PHF5A-HA-Esc-C46A/C49A, C58A/C61A and C72A/C75A (zinc fingers 3, 1 and 2
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Cells
HeLa (ATCC), 293T (ATCC), A375 (ATCC) and primary human cardiac fibroblast cells
(ScienCell Research Laboratories) were cultured in Dulbecco’s modified Eagle’s medium con-
taining 10% fetal bovine serum (FBS) (GIBCO) and antibiotics (penicillin 100 U/mL and strep-
tomycin 100 μg/mL) (Corning Cellgro). HeLa cells stably expressing a series of PHF5A
mutants were generated by transduction of corresponding lentiviral vector, followed by puro-
mycin selection. Human islets were obtained through Integrated Islet Distribution Program
and cultured in RPMI1640 medium supplemented with 10% FBS and antibiotics. Murine islets
were harvested through intraductal collagenase perfusion and enzymatic digestion of the pan-
creas as previously described [59], and maintained in RPMI1640 medium supplemented with
10% FBS and antibiotics. Porcine hepatocytes were isolated from 15–20 kg pigs by a 2-step col-
lagenase perfusion technique as previously described [60], and cultured in DMEMmedium
supplemented with 10% FBS, 10mMHEPES and antibiotics. Primary cardiomyocytes were
isolated from newborn Dahl salt-sensitive rats using the Neonatal Cardiomyocytes Isolation
System (Worthington, Lakewood, NJ) according to the manufacturer’s instruction. Beating
cardiomyocytes were plated in gelatin/fibronectin-coated plates in DMEMmedium supple-
mented with 10% FBS.
Viral vectors
Helper-free AAV vectors were produced by transfection of three plasmids as described
previously [61]. Briefly, 293T cells were transfected with three plasmids, including pHelper
(Stratagene), one of the RepCap-expression plasmids (pRep2Cap2, pRep2Cap6, pRep2
Cap9, or pRep2Cap8, kindly provided by Dr. James Wilson) and a transfer vector plasmid
(pAAV-CMV-Luc, pAAV-SFFV-Luc, pAAV-CMV-Emerald GFP, or pScAAV-CMV-GFP
[62]. pScAAV-CMV-GFP plasmid was kindly provided by Dr. R Jude Samulski through the
National Gene Vector Biorepository. The resulting vectors were gradient purified using
iodixanol (Optiprep Density Gradient Medium, SigmaAldrich), desalted and concentrated
using Amicon Ultra-15 100k filtration (Amicon, Billerica, MA, USA) and resuspended in
PBS. The genome copies (gc) of concentrated AAV vector stocks were determined by quanti-
tative PCR as described previously [24]. Luciferase- or shRNA-carrying lentiviral vectors
were produced as described previously [63]. Human adenovirus 5 (ATCC VR1516) was pur-
chased from ATCC. Unless otherwise stated, no helper virus co-infection was used during
AAV vector transduction.
siRNA library
Human siGENOME Ubiquitin Conjugation Subsets #1 (89 genes), #2 (115 genes) and #3 (396
genes), a SMARTpool siRNA Library in Reverse Transfection Format (RTF) covering 600 gene
targets, were purchased from Thermo Fisher Scientific. According to the provided RTF proto-
col, 5,000 cells/well HeLa cells were seeded, followed by AAV9 CMV-Luc infection at a multi-
plicity of infection of 100 (gc/cell). 48 hours after infection, luciferase assay was performed
using the ONE-Glo Luciferase Assay System (Promega).
siRNA and shRNA treatment and luciferase assay
HeLa cells were seeded in a 96-well plate at 5,000 cells/well for one day. Cells were then trans-
fected with 0.5 μL of 10 μM siRNA using DharmaFECT Transfection Reagents (Thermo Fisher
Scientific) according to the manufacturer’s instruction. Following siRNAs were used; control
siRNA (siKrt1 5 SI02636732 from Qiagen), siPHF5A#1 and #2 (PHF5A 6 SI04210892 and
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7 SI04310621) from Qiagen, siGenome Smart Pool siRNAs for PHF5A-interacting proteins;—
siHIST1H4B (NM_003544, cat# M-011463-00), siU2AF1 (NM_001025203, cat# M-012325-
01), siSF3B1 (NM_001005526, cat# M-020061-02), siSF3B2 (NM_006842, cat# M-026599-03),
siSF3B3 (NM_012426, cat# M-020085-01). Twenty four hours post transfection, cells were
infected with luciferase- or GFP-expressing vectors for 2 days.
Splicing inhibitors
Meayamycin B was described previously [58]. Isoginkgetin was purchased from Millipore and
resuspended in DMSO. 3-Aminophenylboronic acid was purchased from Sigma and resus-
pended in DMSO.
RT-qPCR
cDNA synthesis was performed with one μg RNA using RNA to cDNA EcoDry Premix (Clon-
tech). Primers used were as follows: Fig 1B PHF5A (cat# Hs00754435_s1, Invitrogen); Fig 2C
luciferase (cat# Mr03987587_mr, Invitrogen); Fig 4B and 4C AAV polyA (Forward 5’-
CCTGGGTTCAAGCGATTCTC-3’, Reverse 5’-AGCTGAGCCTGGTCATGCAT-3’, Probe
5’-/FAM/TGCCTCAGCCTCCCGAGTTGT, IDT).
Western blotting
Western blotting was performed as described previously [64]. Following primary antibodies
were used: rabbit anti-PHF5A (Sigma HPA028885-100UL) 1:50, rat anti-HA clone 3F10
(Roche 11867423001) 1:250, rabbit anti-VP1, 2, 3 (American Research Products, Inc. 03–
61084) 1:250, mouse anti-SAP155 (SF3B1) (MBL International D221-3) 1:250. ImageJ software
was used to quantify Western blots from immunoprecipitations.
Southern blotting
DIG High Prime DNA Labeling and Detection Starter Kit II (Roche) was used for Southern
blotting to detect the luciferase DNA in the AAV vector genome. A luciferase DNA fragment
from pSIN-Luc was labeled according to the manufacturer’s instruction. HeLa cells were
seeded in a 6-well plate at 200,000 cells per well, followed by transfection with control or
PHF5A siRNAs. 24 hours post transfection, AAV9 CMV-Luc (MOI 8 x 104) was added for 1, 3
or 6 hours. Cells were harvested in lysis buffer for nuclear fractionation. Nuclear lysates were
purified as in “Cell fractionation and analysis of nuclear rAAV genomes” section. 2 μg of DNA
sample was run on a 2% agarose gel without ethidium bromide at 50V for 1.5 hours. The gel
was prepared for transfer in the following washes with rocking: 0.25N HCl 10 min, rinse
ddH20, denaturation buffer (0.5N NaOH, 1.5M NaCl) 15 min, denaturation buffer 30 min,
neutralization buffer (0.5M Tris, 1.5M NaCl) 15 min, and neutralization buffer 30 min. The gel
was then blotted overnight by capillary transfer with 10x SSC on a positively charge nylon
membrane (Roche). DNA was fixed to the membrane by UV-crosslinking and the luciferase
probe was hybridized to the DNA overnight at 43.5°C. The membrane was washed and devel-
oped according to the protocol (Roche).
Northern blotting
Cells were prepared for Northern blot by seeding at 200,000 cells per well in a 6-well plate,
transfected with control and PHF5A siRNAs, followed by transduction with AAV9 CMV-
Luc vector (MOI 4 x 105). 36 hours post transduction cells were harvested and nuclear and
cytoplasmic RNA was isolated using the PARIS kit (Ambion). 1 μg RNA was run on a
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formaldehyde gel, washed, and blotted by capillary transfer overnight according to the DIG
Northern Starter Kit (Roche). The RNA was fixed to the membrane by UV-crosslinking and
the DIG-labeled luciferase DNA probe from Southern blotting was incubated with the pre-
treated membrane overnight at 50°C. The membrane was washed and developed according to
the manufacturer’s instructions.
Cell fractionation and analysis of nuclear rAAV genomes
Cells were resuspended in cytoplasmic lysis buffer (1.3M sucrose, 20mMMgCl2, 4mM Tris,
4.2% Triton X-100) and incubated on ice for 10 min. The lysates were homogenized using a
21-guage needle and syringe, spun at 14,000 rpm for 15 min at 4°C and the supernatant (cyto-
plasmic fraction) was collected. The pellet (nuclear fraction) was washed with PBS. RNA was
eliminated by RNaseA (200U/mL) treatment. A Qiagen QIAamp DNAMini kit was used to
further purify the DNA. Quantitative real-time PCR was performed to determine AAV lucifer-
ase genomic copy numbers. To assess encapsidated AAV genomes in the nucleus, the above
procedure was followed with the addition of DNase (Invitrogen) treatment at 37°C for 30 min
(both control and DNase treated samples) at the beginning of DNA purification and quantita-
tive real-time PCR detection.
Transgene expression from single-stranded AAV genomic DNA
AAV genomic DNA was isolated using the QIAamp DNAmini kit following the provided Pro-
tocols for Viral DNA (Qiagen). The genomic DNA was isolated from 4 x 1011 vector genomes
of purified AAV9 CMV-Luc vector. HeLa cells transfected with control or PHF5A siRNAs
were transfected with the purified AAV genomic DNA (0.1 μg/well) by FuGENE6 (Promega),
and luciferase expression was analyzed 48 hours after viral DNA transfection.
Immuno-precipitation
Semi-confluent HeLa cells with or without stable overexpression of the HA-tagged PHF5A
were infected with AAV2 or AAV9 CMV-Luc (MOI 4 x 105) in a 6-well plate for 6 hours at
37°C. Cells were then harvested on ice in RIPA buffer containing protease inhibitor, followed
by pull-down with 20 μL anti-HA agarose beads (Pierce). After 15 cycles of washing, pellets
were resuspended in 0.5 mL PBS and split into 2 aliquots. One aliquot was used for Western
blotting of AAV capsid proteins, and the other was used for the isolation of total DNA by
QIAamp DNAMini kit for RT-qPCR detection of AAV genomic DNA. For pull-down assay
using heated AAV particles, 100 μL cell lysate was combined with 3 x 1010 gc of AAV2
CMV-Luc vector particles that were unheated or pre-heated for 30 min at 65°C, followed by
precipitation by anti-HA agarose as above.
Confocal microscopy
The Lab-TekII 8-well chamber slides (Thermo Fisher Scientific) were pretreated for 5 min
with poly-d-lysine (Sigma, 0.1 mg/mL). HeLa cells were plated at 1 x 104 cells/well and were
infected with AAV2 CMV-Luc (4 x 1010 gc/well) or empty AAV2 (25 μl/well) at 37°C for 5
min, 4 hours, or 12 hours. Cells were fixed in 4% paraformaldehyde for 20 min at room tem-
perature, permeabilized with 0.3% Triton X-100 for 15 min, and blocked with 5% FBS/PBS for
30 min. Primary antibody was added, and cells were incubated for 1.5 hours at room tempera-
ture in a humidified chamber. Secondary antibody followed according to the same procedure.
Then cells were washed three times with PBS, treated with DAPI (Sigma, 1:2000) for 1 min,
washed three times with PBS, and mounted with Dako fluorescent mounting media. Confocal
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microscopy was performed on an LSM 780 confocal microscope (Zeiss). The following primary
and secondary antibodies were used for immunocytochemistry of uninfected and AAV
infected HeLa cells: anti-AAV particles (A20) mouse monoclonal antibody (American
Research Products) at 1:100 followed by FITC-conjugated donkey anti mouse IgG (H+L)
(Jackson 715-095-151) 1:500; rabbit anti-PHF5A (Sigma HPA028885-100UL) 1:250 and Alexa
Fluor 594-conjugated donkey anti-rabbit IgG (H+L) (Invitrogen A-21207) 1:2000; rabbit anti-
phospho-SF3B1 (MBL International PD043) 1:500 and Alexa Fluor 594-conjugated donkey
anti-rabbit IgG (H+L) 1:500.
Iodixanol cushion co-precipitation assay
AAV2 CMV-Luc vectors (5 x 1010 gc/tube) and purified AAV2 empty, VP3 only particles were
left unheated or pre-heated at 65°C for 30 min and placed on ice. HeLa and HeLa-PHF5A-HA
cells were harvested by incubating 1 well of a 6-well plate with 500 μL RIPA buffer supplemented
with protease inhibitors on ice for 10 min. Cells were harvested by scraping, homogenized using a
21-guage needle and syringe, and spun for 5 min at 13,200 rpm. 400 μL of the cell lysate was
added to the virus and samples were rotated for 1 hour at 4°C. The 25% iodixanol solution was
prepared using 3.2 mL 1x PBS, 2.8 mL 9:1 Optiprep to 10x PBS, and 0.15% phenol red. 30 μL of
the lysate virus mixture was removed and used as an input. The remaining lysate-virus mix was
layered on top of 0.5 mL 25% iodixanol. These samples were spun at 4°C for 1 hour at 14,000 rpm.
After spinning the clear upper layer, red lower layer, and pellet were harvested for Western blot.
The following antibodies were used in this experiment: rabbit anti-PHF5A (Sigma HPA028885)
1:100, rat anti-HA clone 3F10 (Roche 11867423001) 1:500, rabbit anti-VP1, 2, 3 (American
Research Products, Inc. 03–61084) 1:250, mouse anti-SF3B1 (MBL International D221-3) 1:500,
rabbit anti-phospho-SF3B1 (MBL International PD043) 1:400, rabbit anti-histone H2B (Cell Sig-
naling #8135) 1:1000, and rabbit anti-histone H3 (Cell Signaling #4499) 1:1000 in blocking buffer.
To note, the membrane that received phospho-SF3B1 primary antibody was blocked in 5% BSA/
PBS + 0.05% Tween-20. Antibodies were diluted in 1x TBS + 0.001% Tween-20.
Verification of inhibition of pre-mRNA splicing by inhibitors
HeLa cells at 80% confluency were treated with pre-mRNA splicing inhibitors at the following
concentrations: 3-Aminophenylboronic acid (5mM and 1mM), Isoginkgetin (25uM and
12.5uM), and meayamycin B (10nM and 5nM). Eight hours post drug RNA was isolated using
TRIzol (Invitrogen), and cDNA synthesis was performed with one μg RNA using RNA to
cDNA EcoDry Premix (Clontech). cDNA was amplified by KOD Hot Start DNA Polymerase
(EMDMillipore) using primers for MAPT exon 10 5’-AAGATCGGCTCCACTGAGAA-3’
and 5’-ATGAGCCACACTTGGAGGTC-3’.
Supporting Information
S1 Fig. Characterization of RAB40A and PRICKL4 disruptions on AAV vector transduc-
tion. (A) Quantitative real-time RT-PCR was performed to determine the levels of RAB40A and
PRICKLE4 transcripts in HeLa cells infected with a control lentiviral vector pLKO.1 or vectors
carrying RAB40A and PRICKE4-targeting shRNAs at 48 hours. (B) Upon infection with AAV9
CMV-Luc vector for two days, relative luciferase activity was determined in HeLa cells pre-
treated with the shRNA lentivectors. (C) Same as B, but luciferase-expressing adenoviral and len-
tiviral vectors were used. Data are shown as averages of three independent experiments with
error bars representing standard error of the mean.  (p<0.05). For the introduction of shRNAs,
cells were transduced with lentiviral control vector (pLKO.1), or vectors carrying shRAB40A or
shPRICKLE4 fromOpenBiosystems (plasmid names) at estimated MOI of 4. 24 hours post
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lentiviral transduction, cells were infected with luciferase-expressing vectors. Luciferase
expression was measured by the ONE-Glo Luciferase Assay System (Promega) according to
the manufacturer’s instruction. Pre-designed primers from Invitrogen were purchased
(RAB40A, 4331182 Hs00369904_m1; PRICKLE4, 4331182 Hs00255728_m1) and used for
the qRT-PCR. Over-expression of the PRICKLE4-Escape mutant did not reverse the effects
of the PRICKLE4 shRNA in HeLa cells stably expressing an shRNA-resistant PRICKLE4
mutant. Thus, the effects observed with the PRICKLE4 disruption were likely due to off-tar-
get effects. We have not tested the effect of over-expression of RAB40A-Escape mutant.
(PDF)
S2 Fig. Verification of the cytoplasmic and nuclear fractions by immunoblotting. Cyto-
plasmic and nuclear fractions were analyzed 2 hours p.i. to determine subcellular fractionation
purity. GAPDH (cat# AM4300, Ambion, 1:1000) and Histone H3 (cat# 4499, Cell Signaling,
1:1000) antibodies were used as cytoplasmic and nuclear markers to verify the cytoplasmic and
nuclear fractions respectively.
(PDF)
S3 Fig. GATA-type zinc fingers in PHF5A are essential for the restriction of AAV vectors.
(A) The alignment of PHD finger-like domains of PHF5A and its yeast homolog Rds3 is
shown. Five conserved CxxC repeats are underlined. (B) Predicted triquetra knot structure of
PHF5A, based on the yeast Rds3 structure (van Roon et al., PNAS 2008, 105:9621–6), is shown
with the three GATA-type zinc fingers. (C) HeLa cells were transduced by lentiviral vectors
expressing a series of zinc finger mutants of the PHF5A-HA-Escape, followed by puromycin
selection. Expression of HA-tagged PHF5A proteins and their resistance to the PHF5A siRNA
were verified by transfecting individual HeLa lines with control or PHF5A siRNAs. (D) Control
HeLa cells, HeLa lines stably expressing PHF5A-HA Escape, or PHF5A-HA Escape zinc finger
mutants, were pre-treated with control or PHF5A siRNAs for 24 hours, followed by transduc-
tion by the AAV9 CMV-Luc vector. Relative luciferase expression was determined 48 h ours
p.i. Data are shown as averages of three independent experiments with error bars representing
standard error of the mean.
(PDF)
S4 Fig. Genetic and pharmacological inhibition of spliceosomal proteins on AAV vector
transduction. (A) HeLa cells were transfected with control or siRNAs targeting the potential
PHF5A-interacting proteins. Commercially available specific primers and probe sets were used
for the quantitative real-time RT-PCR to determine the transcript levels. From Bio-Rad
LMNA, FUS, EEF1A1, EEF2, HIST1H4B, U2AF1, SRSF5, SF3B1, SF3B2, SF3B3, EP400,
DDX1, SNRNP200 and PRPF31 primers; from Invitrogen PHF5A primers and probe. The lev-
els of individual transcripts in untreated cells were set as 100%. Error bars represent standard
deviation. (B) HeLa cells were transfected with control siRNA, or a series of siRNAs for 24
hours, followed by the AAV9 CMV-Luc vector transduction. Relative luciferase expression was
determined 48 h ours p.i. (C) HeLa cells were transduced with AAV2 or AAV9 CMV-Luc
(MOI 104) and given meayamycin (20 nM) 9 hours p.i. Luciferase assay was performed 48
hours p.i. (D) HeLa cells were transduced with AAV9 CMV-Luc vectors, in the presence of
increasing doses of ABA. Relative luciferase expression was determined 72 hours p.i. (E) HeLa
cells were transduction with AAV2 or AAV9 CMV-Luc vectors, followed by 20 nMmeayamy-
cin B treatments at various time points (3–24, 3–48, 3–72, 24–48, 24–72, or 48–72 hours p.i.).
Cells were harvested and relative luciferase expression was determined 72 hours p.i. (F) Co-
treatment of HeLa cells with PHF5A siRNAs and Meayamycin B. HeLa cells were treated with
the siRNA for 48 hr, followed by infection with AAV9 CMV-Luc (MOI 104). At 9 hours p.i.
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Meayamycin B (5nM) was added, and cells were harvested for the luciferase assay 48 hours p.i.
(G) Influence of dual treatment with human adenovirus 5 infection and meayamicin on AAV
vector infection. HeLa cells were infected with AAV2 CMV-Luc (MOI 104) or co-infection
with AAV2 CMV-Luc and human adenovirus 5 (MOI 3 x 104), in the presence or absence of
meayamycin (20 nM) for 48 hours. (H) Influence of adenovirus 5 infection on subcellular
localization of PHF5A in HeLa cells. HeLa cells stably expressing the HA-tagged PHF5A were
infected with human adenovirus 5 (MOI 104) for 24 hours, and PHF5A-HA in control and
infected HeLa cells was visualized by anti-HA antibody (red). (I) Influence of U2 snRNP inhi-
bition on AAV vector production. AAV2 vectors were made by triple transfection with pHel-
per, pXX2, and pAAV CMV-Luc, triple transfection with Meayamycin B (5 nM), or double
transfection (no pHelper) with Meayamycin B (5 nM). Viruses were added to HeLa cells (2 uL/
well) and 48 hours later their infectivity was determined by luciferase assay.
(PDF)
S5 Fig. Pull-down of the HA-tagged PHF5A protein. (A) HeLa or HeLa overexpressing
PHF5A-HA lysates were used to pull-down the HA-tagged PHF5A by anti-HA agarose beads.
After immunoprecipitation samples were spun for 5 min and the supernatant and pellet were
separated and run on a Western blot for HA detection of the PHF5A-HA tagged protein. Rela-
tive PHF5A-HA levels were quantified using ImageJ software. (B) Same as A except samples
were washed 15 times following IP and washes 5, 10 and 15 were saved an run along side the
input and pull-down for Western blotting. The percent PHF5A-HA pulled down relative to the
input was calculated by ImageJ software.
(PDF)
S6 Fig. Subcellular localization of PHF5A. (A) Control and AAV2 vector-treated HeLa cells
were monitored for the subcellular localization of endogenous PHF5A. Note increased cyto-
plasmic PHF5A signals upon AAV2 vector infection. (B) Same as Fig 4E, but without AAV
vector infection. (C) Same as Fig 4E, but with (right) or without (left) pre-treatment with siR-
NA-PHF5A.
(PDF)
S7 Fig. Influence of disruption of PHF5A expression on AAV vector trafficking in HeLa
cells. (A) Control HeLa cells were infected with the AAV2 vector for 4 hours. AAV2 vector
particles were detected by anti-AAV2 capsid A20 antibody, and the patterns of cytoplasmic
and nuclear accumulations of AAV2 vector particles were visualized using Z-stack images. Top
(slice 1) to bottom (slice 5) images were shown above. The middle sections (slices 3 and 4)
were shown in higher magnification. (B) Same as A, but HeLa cells were pre-treated with the
PHF5A siRNA for 24 hours. (C) Control and PHF5A siRNA-treated HeLa cells were infected
with the AAV2 CMV-Luc vector for 4 hours, followed by confocal microscopic analysis of
AAV2 capsid and PHF5A. Note the PHF5A siRNA-treatment suppressed the PHF5A signals.
Again, no notable changes in AAV2 vector particle trafficking were observed.
(PDF)
S8 Fig. Localization of SF3B1 and AAV2 capsid. (A) HeLa cells were infected with the AAV2
CMV-Luc vector for 5 min, 4 hr, or 12 hr. Confocal microscopy analysis was performed to
detect the subcellular localizations of intact AAV vector particles (green) and SF3B1 (red) by
specific antibodies. Nuclei were counterstained by DAPI (blue). (B) HeLa cells were infected
with the AAV2 CMV-Luc vector for 4 hours, and cells were analyzed for co-localization of
AAV2 capsid and endogenous SF3B1 signals. (C) Same as Fig 4H, except that heated or
unheated AAV2 CMV-Luc vectors or heated or unheated empty AAV2 vectors were used.
SF3B1 was more efficiently co-precipitated with pre-heated AAV2 particles, suggesting that
U2 snRNPMediates AAV Restriction
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heat-induced conformational changes in AAV2 capsids increase the interaction. Empty AAV2
capsids were able to enrich SF3B1 in the pellets, suggesting again there is no role for AAV
genomic DNA in the interaction between SF3B1 and AAV2 capsid. (D) Same as Fig 4H, except




The authors would like to thank Dr. Paul Lehner (Cambridge Institute for Medical Research)
for helpful suggestions and for providing the lentiviral pSIN-CSGW-PGK-puro plasmid. We
also thank the National Gene Vector Biorepository for providing the AAV vector plasmids.
We also thank Dr. Moustafa El-Khatib and Mr. Jason Tonne for excellent technical supports
and helpful discussion.
Author Contributions
Conceived and designed the experiments: CAS TS SJH RDH YIz AA YIk. Performed the exper-
iments: CAS TS SJH RDH YIz. Analyzed the data: CAS TS SJH RDH YIz KK AA YIk. Contrib-
uted reagents/materials/analysis tools: RKB UB. Wrote the paper: CAS YIz KK AA YIk.
References
1. Bridge E, Xia DX, Carmo-Fonseca M, Cardinali B, Lamond AI, et al. (1995) Dynamic organization of
splicing factors in adenovirus-infected cells. J Virol 69: 281–290. PMID: 7983720
2. Burch AD, Weller SK (2004) Nuclear sequestration of cellular chaperone and proteasomal machinery
during herpes simplex virus type 1 infection. J Virol 78: 7175–7185. PMID: 15194794
3. Geoffroy MC, Salvetti A (2005) Helper functions required for wild type and recombinant adeno-associ-
ated virus growth. Current gene therapy 5: 265–271. PMID: 15975004
4. Xiao PJ, Samulski RJ (2012) Cytoplasmic trafficking, endosomal escape, and perinuclear accumulation
of adeno-associated virus type 2 particles are facilitated by microtubule network. J Virol 86: 10462–
10473. doi: 10.1128/JVI.00935-12 PMID: 22811523
5. Venkatakrishnan B, Yarbrough J, Domsic J, Bennett A, Bothner B, et al. (2013) Structure and dynamics
of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking. J
Virol 87: 4974–4984. doi: 10.1128/JVI.02524-12 PMID: 23427155
6. Bartlett JS, Wilcher R, Samulski RJ (2000) Infectious entry pathway of adeno-associated virus and
adeno-associated virus vectors. J Virol 74: 2777–2785. PMID: 10684294
7. Thomas CE, Storm TA, Huang Z, Kay MA (2004) Rapid uncoating of vector genomes is the key to effi-
cient liver transduction with pseudotyped adeno-associated virus vectors. J Virol 78: 3110–3122.
PMID: 14990730
8. Ferrari FK, Samulski T, Shenk T, Samulski RJ (1996) Second-strand synthesis is a rate-limiting step for
efficient transduction by recombinant adeno-associated virus vectors. J Virol 70: 3227–3234. PMID:
8627803
9. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, et al. (1996) Transduction with recombinant
adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 70: 520–532.
PMID: 8523565
10. Douar AM, Poulard K, Stockholm D, Danos O (2001) Intracellular trafficking of adeno-associated virus
vectors: routing to the late endosomal compartment and proteasome degradation. J Virol 75: 1824–
1833. PMID: 11160681
11. Mitchell AM, Samulski RJ (2013) Mechanistic insights into the enhancement of adeno-associated virus
transduction by proteasome inhibitors. J Virol 87: 13035–13041. doi: 10.1128/JVI.01826-13 PMID:
24027330
12. Nonnenmacher M, Weber T (2012) Intracellular transport of recombinant adeno-associated virus vec-
tors. Gene Ther 19: 649–658. doi: 10.1038/gt.2012.6 PMID: 22357511
U2 snRNPMediates AAV Restriction
PLOS Pathogens | DOI:10.1371/journal.ppat.1005082 August 5, 2015 22 / 25
13. Qing K, Hansen J, Weigel-Kelley KA, Tan M, Zhou S, et al. (2001) Adeno-associated virus type 2-medi-
ated gene transfer: role of cellular FKBP52 protein in transgene expression. J Virol 75: 8968–8976.
PMID: 11533160
14. Schwartz RA, Palacios JA, Cassell GD, Adam S, Giacca M, et al. (2007) The Mre11/Rad50/Nbs1 com-
plex limits adeno-associated virus transduction and replication. J Virol 81: 12936–12945. PMID:
17898048
15. Lentz TB, Samulski RJ (2015) Insight into the mechanism of inhibition of adeno-associated virus by the
Mre11/Rad50/Nbs1 complex. J Virol 89: 181–194. doi: 10.1128/JVI.01990-14 PMID: 25320294
16. Chen H, Lilley CE, Yu Q, Lee DV, Chou J, et al. (2006) APOBEC3A is a potent inhibitor of adeno-asso-
ciated virus and retrotransposons. Current biology: CB 16: 480–485. PMID: 16527742
17. Mitchell AM, Hirsch ML, Li C, Samulski RJ (2014) Promyelocytic leukemia protein is a cell-intrinsic fac-
tor inhibiting parvovirus DNA replication. J Virol 88: 925–936. doi: 10.1128/JVI.02922-13 PMID:
24198403
18. Asokan A, Schaffer DV, Samulski RJ (2012) The AAV vector toolkit: poised at the clinical crossroads.
Molecular therapy: the journal of the American Society of Gene Therapy 20: 699–708.
19. Asokan A, Conway JC, Phillips JL, Li C, Hegge J, et al. (2010) Reengineering a receptor footprint of
adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol 28:
79–82. doi: 10.1038/nbt.1599 PMID: 20037580
20. GrimmD, Lee JS, Wang L, Desai T, Akache B, et al. (2008) In vitro and in vivo gene therapy vector evo-
lution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 82: 5887–
5911. doi: 10.1128/JVI.00254-08 PMID: 18400866
21. Lisowski L, Dane AP, Chu K, Zhang Y, Cunningham SC, et al. (2014) Selection and evaluation of clini-
cally relevant AAV variants in a xenograft liver model. Nature 506: 382–386. doi: 10.1038/nature12875
PMID: 24390344
22. Adachi K, Enoki T, Kawano Y, Veraz M, Nakai H (2014) Drawing a high-resolution functional map of
adeno-associated virus capsid by massively parallel sequencing. Nature communications 5: 3075. doi:
10.1038/ncomms4075 PMID: 24435020
23. Yang L, Jiang J, Drouin LM, Agbandje-McKenna M, Chen C, et al. (2009) A myocardium tropic adeno-
associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci U S A 106:
3946–3951. doi: 10.1073/pnas.0813207106 PMID: 19234115
24. Cataliotti A, Tonne JM, Bellavia D, Martin FL, Oehler EA, et al. (2011) Long-term cardiac pro-B-type
natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontane-
ously hypertensive rats. Circulation 123: 1297–1305. doi: 10.1161/CIRCULATIONAHA.110.981720
PMID: 21403100
25. Takeda S, Takahashi M, Mizukami H, Kobayashi E, Takeuchi K, et al. (2004) Successful gene transfer
using adeno-associated virus vectors into the kidney: comparison among adeno-associated virus sero-
type 1–5 vectors in vitro and in vivo. Nephron Experimental nephrology 96: e119–126. PMID:
15122061
26. Ashtari M, Cyckowski LL, Monroe JF, Marshall KA, Chung DC, et al. (2011) The human visual cortex
responds to gene therapy-mediated recovery of retinal function. J Clin Invest 121: 2160–2168. doi: 10.
1172/JCI57377 PMID: 21606598
27. Nathwani AC, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, et al. (2011) Long-term safety and
efficacy following systemic administration of a self-complementary AAV vector encoding human FIX
pseudotyped with serotype 5 and 8 capsid proteins. Molecular therapy: the journal of the American
Society of Gene Therapy 19: 876–885.
28. Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, et al. (2012) Phase 1 gene therapy for Duchenne
muscular dystrophy using a translational optimized AAV vector. Molecular therapy: the journal of the
American Society of Gene Therapy 20: 443–455.
29. Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, et al. (2014) Long-term effects of AAV1/
SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular
events and mortality. Circ Res 114: 101–108. doi: 10.1161/CIRCRESAHA.113.302421 PMID:
24065463
30. Smith BK, Collins SW, Conlon TJ, Mah CS, Lawson LA, et al. (2013) Phase I/II trial of adeno-associated
virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in
Pompe disease: initial safety and ventilatory outcomes. HumGene Ther 24: 630–640. doi: 10.1089/
hum.2012.250 PMID: 23570273
31. Grieger JC, Samulski RJ (2012) Adeno-associated virus vectorology, manufacturing, and clinical appli-
cations. Methods in enzymology 507: 229–254. doi: 10.1016/B978-0-12-386509-0.00012-0 PMID:
22365777
U2 snRNPMediates AAV Restriction
PLOS Pathogens | DOI:10.1371/journal.ppat.1005082 August 5, 2015 23 / 25
32. Mingozzi F, High KA (2013) Immune responses to AAV vectors: overcoming barriers to successful
gene therapy. Blood 122: 23–36. doi: 10.1182/blood-2013-01-306647 PMID: 23596044
33. Deyle DR, Russell DW (2009) Adeno-associated virus vector integration. Current opinion in molecular
therapeutics 11: 442–447. PMID: 19649989
34. Hubert CG, Bradley RK, Ding Y, Toledo CM, Herman J, et al. (2013) Genome-wide RNAi screens in
human brain tumor isolates reveal a novel viability requirement for PHF5A. Genes & development 27:
1032–1045.
35. Wang Q, Rymond BC (2003) Rds3p is required for stable U2 snRNP recruitment to the splicing appara-
tus. Molecular and cellular biology 23: 7339–7349. PMID: 14517302
36. Rzymski T, Grzmil P, Meinhardt A, Wolf S, Burfeind P (2008) PHF5A represents a bridge protein
between splicing proteins and ATP-dependent helicases and is differentially expressed during mouse
spermatogenesis. Cytogenetic and genome research 121: 232–244. doi: 10.1159/000138890 PMID:
18758164
37. Osman S, Albert BJ, Wang Y, Li M, Czaicki NL, et al. (2011) Structural requirements for the antiproli-
ferative activity of pre-mRNA splicing inhibitor FR901464. Chemistry 17: 895–904. doi: 10.1002/chem.
201002402 PMID: 21226105
38. Schneider-Poetsch T, Usui T, Kaida D, Yoshida M (2010) Garbled messages and corrupted transla-
tions. Nature chemical biology 6: 189–198. PMID: 20154667
39. Kronenberg S, Bottcher B, von der Lieth CW, Bleker S, Kleinschmidt JA (2005) A conformational
change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J
Virol 79: 5296–5303. PMID: 15827144
40. Horowitz ED, Rahman KS, Bower BD, Dismuke DJ, Falvo MR, et al. (2013) Biophysical and ultrastruc-
tural characterization of adeno-associated virus capsid uncoating and genome release. J Virol 87:
2994–3002. doi: 10.1128/JVI.03017-12 PMID: 23269804
41. Sebastian S, Luban J (2005) TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Ret-
rovirology 2: 40. PMID: 15967037
42. Osman S, WaudWR, Gorman GS, Day BW, Koide K (2011) Evaluation of FR901464 analogues in vitro
and in vivo. MedChemComm 2: 38.
43. Russell DW, Alexander IE, Miller AD (1995) DNA synthesis and topoisomerase inhibitors increase
transduction by adeno-associated virus vectors. Proc Natl Acad Sci U S A 92: 5719–5723. PMID:
7777575
44. Zentilin L, Marcello A, Giacca M (2001) Involvement of cellular double-stranded DNA break binding pro-
teins in processing of the recombinant adeno-associated virus genome. J Virol 75: 12279–12287.
PMID: 11711618
45. Zhou C, Yang Q, Trempe JP (1999) Enhancement of UV-induced cytotoxicity by the adeno-associated
virus replication proteins. Biochimica et biophysica acta 1444: 371–383. PMID: 10095060
46. Mah C, Qing K, Khuntirat B, Ponnazhagan S, Wang XS, et al. (1998) Adeno-associated virus type 2-
mediated gene transfer: role of epidermal growth factor receptor protein tyrosine kinase in transgene
expression. J Virol 72: 9835–9843. PMID: 9811719
47. Ju XD, Lou SQ, WangWG, Peng JQ, Tian H (2004) Effect of hydroxyurea and etoposide on transduc-
tion of human bone marrow mesenchymal stem and progenitor cell by adeno-associated virus vectors.
Acta pharmacologica Sinica 25: 196–202. PMID: 14769209
48. Zhong L, ZhaoW,Wu J, Li B, Zolotukhin S, et al. (2007) A dual role of EGFR protein tyrosine kinase sig-
naling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Molecular therapy: the
journal of the American Society of Gene Therapy 15: 1323–1330.
49. Johnson JS, Li C, DiPrimio N, Weinberg MS, McCown TJ, et al. (2010) Mutagenesis of adeno-associ-
ated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-
specific transduction. J Virol 84: 8888–8902. doi: 10.1128/JVI.00687-10 PMID: 20573820
50. Salganik M, Aydemir F, Nam HJ, McKenna R, Agbandje-McKenna M, et al. (2014) Adeno-associated
virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant
genomes. J Virol 88: 1071–1079. doi: 10.1128/JVI.02093-13 PMID: 24198419
51. Isono K, Mizutani-Koseki Y, Komori T, Schmidt-Zachmann MS, Koseki H (2005) Mammalian poly-
comb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1. Genes &
development 19: 536–541.
52. Convertini P, Shen M, Potter PM, Palacios G, Lagisetti C, et al. (2014) Sudemycin E influences alterna-
tive splicing and changes chromatin modifications. Nucleic acids research 42: 4947–4961. doi: 10.
1093/nar/gku151 PMID: 24623796
53. Heo K, Kim B, Kim K, Choi J, Kim H, et al. (2007) Isolation and characterization of proteins associated
with histone H3 tails in vivo. J Biol Chem 282: 15476–15483. PMID: 17403666
U2 snRNPMediates AAV Restriction
PLOS Pathogens | DOI:10.1371/journal.ppat.1005082 August 5, 2015 24 / 25
54. Akusjarvi G, Stevenin J (2003) Remodelling of the host cell RNA splicing machinery during an adenovi-
rus infection. Current topics in microbiology and immunology 272: 253–286. PMID: 12747553
55. Aspegren A, Rabino C, Bridge E (1998) Organization of splicing factors in adenovirus-infected cells
reflects changes in gene expression during the early to late phase transition. Exp Cell Res 245: 203–
213. PMID: 9828117
56. Phelan A, Carmo-Fonseca M, McLaughlan J, Lamond AI, Clements JB (1993) A herpes simplex virus
type 1 immediate-early gene product, IE63, regulates small nuclear ribonucleoprotein distribution. Proc
Natl Acad Sci U S A 90: 9056–9060. PMID: 8415652
57. Bryant HE, Wadd SE, Lamond AI, Silverstein SJ, Clements JB (2001) Herpes simplex virus IE63
(ICP27) protein interacts with spliceosome-associated protein 145 and inhibits splicing prior to the first
catalytic step. J Virol 75: 4376–4385. PMID: 11287586
58. Gao Y, Vogt A, Forsyth CJ, Koide K (2013) Comparison of splicing factor 3b inhibitors in human cells.
Chembiochem: a European journal of chemical biology 14: 49–52. doi: 10.1002/cbic.201200558
PMID: 23172726
59. Zmuda EJ, Powell CA, Hai T (2011) A method for murine islet isolation and subcapsular kidney trans-
plantation. Journal of visualized experiments: JoVE.
60. Sielaff TD, Hu MY, Rao S, Groehler K, Olson D, et al. (1995) A technique for porcine hepatocyte harvest
and description of differentiated metabolic functions in static culture. Transplantation 59: 1459–1463.
PMID: 7770934
61. Tonne JM, Sakuma T, Deeds MC, Munoz-Gomez M, Barry MA, et al. (2013) Global gene expression
profiling of pancreatic islets in mice during streptozotocin-induced beta-cell damage and pancreatic
Glp-1 gene therapy. Disease models & mechanisms 6: 1236–1245.
62. McCarty DM, Monahan PE, Samulski RJ (2001) Self-complementary recombinant adeno-associated
virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 8:
1248–1254. PMID: 11509958
63. Ohmine S, Sakuma R, Sakuma T, Thatava T, Solis GP, et al. (2010) Cytoplasmic body component
TRIM5{alpha} requires lipid-enriched microdomains for efficient HIV-1 restriction. J Biol Chem 285:
34508–34517. doi: 10.1074/jbc.M110.158188 PMID: 20810659
64. Tonne JM, Campbell JM, Cataliotti A, Ohmine S, Thatava T, et al. (2011) Secretion of glycosylated pro-
B-type natriuretic peptide from normal cardiomyocytes. Clin Chem 57: 864–873. doi: 10.1373/
clinchem.2010.157438 PMID: 21482747
U2 snRNPMediates AAV Restriction
PLOS Pathogens | DOI:10.1371/journal.ppat.1005082 August 5, 2015 25 / 25
